OPCH Stock Skyrockets 33% on $5.8B McKesson Takeover
💡 Key Takeaway
Option Care Health agreed to a $32.05 per share buyout from McKesson and CD&R, a 37% premium, but the stock already trades near the offer price, so the easy money has been made.
The Acquisition Details
Option Care Health (OPCH) announced Tuesday morning that it has agreed to be acquired by McKesson (MCK) and private equity firm Clayton, Dubilier & Rice (CD&R) for $32.05 per share in cash. The deal values the company at approximately $5.8 billion and represents a 37% premium to Monday's closing price.
Following the news, OPCH stock skyrocketed as much as 33.1% during Tuesday's trading session. As of 1:46 p.m. ET, the stock was still up 33%, trading just above $31 per share.
The transaction is structured so that CD&R will own 51% of the company, while McKesson will hold a 49% stake. The deal also includes a framework that allows McKesson to acquire CD&R's stake in the future, subject to certain conditions and regulatory approvals.
Option Care Health will continue to operate as a separate company, led by its existing management team. The deal is expected to close in the first half of calendar 2027, pending shareholder and regulatory approvals. The company will still report Q3 results on Nov. 4 but will skip its usual live earnings call.
McKesson CEO Brian Tyler said the acquisition aligns with the company's strategic goals, citing the alternate infusion therapies market as an attractive long-term growth opportunity that also provides accessible, affordable care to patients.
Why This Deal Matters for Investors
For Option Care Health shareholders, the buyout offers a clean exit at a significant premium. However, the stock is already trading within 3% of the offer price, which means the market is highly confident the deal will close. That leaves little room for further gains unless a competing bid emerges—which seems unlikely given the size and structure of the deal.
For McKesson, this is a strategic move to expand into the home and alternate-site infusion market, a growing segment of healthcare. By partnering with CD&R, McKesson limits its initial capital outlay while securing a path to full ownership down the road. The deal is expected to be accretive to McKesson's long-term growth, but it won't move the needle much in the near term given McKesson's much larger size.
The acquisition also highlights ongoing consolidation in the healthcare services sector, where scale and cost efficiency are increasingly important. Investors in similar companies may wonder if their holdings could be next.
One risk to watch: the deal isn't expected to close until the first half of 2027, leaving a long timeline for potential regulatory hurdles or changes in market conditions. If the deal falls through, OPCH stock could plummet back to pre-announcement levels.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
OPCH shareholders should consider taking profits now, while MCK remains a solid long-term hold for its strategic expansion.
The merger arbitrage opportunity in OPCH is largely played out, with the stock trading just 3% below the offer price. The deal is not expected to close until 2027, tying up capital for minimal return. For MCK, the acquisition is a smart move that positions it in a high-growth market, but it's unlikely to significantly impact the stock price in the near term.
What This Means for Me
